BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 18987910)

  • 1. A comparison of lipoatrophy and aging: volume deficits in the face.
    Coleman S; Saboeiro A; Sengelmann R
    Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
    Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
    Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between lipoatrophy and quality of life.
    Echavez M; Horstman W
    AIDS Read; 2005 Jul; 15(7):369-75. PubMed ID: 16044579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facial fat volume in HIV-infected patients with lipoatrophy.
    Yang Y; Sitoh YY; Oo Tha N; Paton NI
    Antivir Ther; 2005; 10(4):575-81. PubMed ID: 16038484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full scope of effect of facial lipoatrophy: a framework of disease understanding.
    Ascher B; Coleman S; Alster T; Bauer U; Burgess C; Butterwick K; Donofrio L; Engelhard P; Goldman MP; Katz P; Vleggaar D
    Dermatol Surg; 2006 Aug; 32(8):1058-69. PubMed ID: 16918569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
    Orentreich D; Leone AS
    Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caring for HIV-positive and aging patients with associated facial lipoatrophy.
    Esch P
    Plast Surg Nurs; 2006; 26(1):17-23. PubMed ID: 16543853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
    Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
    HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of facial lipoatrophy via autologous fat transfer.
    Cohen G; Treherne A
    J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
    Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
    Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restorative interventions for HIV facial lipoatrophy.
    Carey D; Liew S; Emery S
    AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
    Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
    J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
    Pavicic T; Ruzicka T; Korting HC; Gauglitz G
    J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
    Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
    AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of HIV facial lipoatrophy with a submalar porous polyethylene implant (Medpor)].
    Claude O; Domergue Than Trong E; Blanc R; Ascher B; Bagot M; Meningaud JP; Lantieri L
    Ann Chir Plast Esthet; 2009 Feb; 54(1):21-8. PubMed ID: 19042066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
    Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
    Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.
    Jones DH; Carruthers A; Orentreich D; Brody HJ; Lai MY; Azen S; Van Dyke GS
    Dermatol Surg; 2004 Oct; 30(10):1279-86. PubMed ID: 15458523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.